

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/09735 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**

(21) International Application Number: **PCT/US01/24147**

(22) International Filing Date: 31 July 2001 (31.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/222,071 1 August 2000 (01.08.2000) US

(71) Applicant (*for all designated States except US*): **UNIVERSITY OF WASHINGTON [US/US]**; Office of Technology Transfer, Suite 200, 1107 NE 45th Street, Seattle, WA 98105-4631 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BORNSTEIN, Paul [US/US]**; 602 - 34th Avenue, Seattle, WA 98112 (US). **KYRIAKIDES, Themis [CY/US]**; 7729 - 45th Avenue S.W., Seattle, WA 98136 (US). **RATNER, Buddy**

[US/US]; 1612 Bigelow Avenue N., Seattle, WA 98109 (US). **GIACHELLI, Cecilia [US/US]**; 3012 154th Street, S.E., Mill Creek, WA 98012 (US). **MARTINSON, Laura [US/US]**; Dexcon Inc., 6725 Meso Ridge Road, San Diego, CA 92121 (US). **SCATENA, Marta [US/US]**; 1825 N. 51st Street, Seattle, WA (US).

(74) Agent: **McGURL, Barry, F.**; Christensen O'Connor Johnson & Kindness PLLC Suite 2800, 1420 Fifth Avenue, Seattle, WA 98101 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

*[Continued on next page]*

(54) Title: METHODS AND DEVICES TO MODULATE THE WOUND RESPONSE



**WO 02/09735 A2**



(57) Abstract: In one aspect, the invention provides methods of modulating the amount and/or biological activity of thrombospondin (2) or osteopontin in an animal. The methods comprise the step of introducing into the animal an amount of osteopontin, and/or a thrombospondin (2) antagonist, effective to modulate the amount or biological activity of thrombospondin (2) or osteopontin in the animal. In another aspect, the invention provides medical devices comprising (a) a device body; and (b) a surface layer attached to the device body, the surface layer including an amount of an agents or antagonist of a matricellular protein sufficient to reduce the foreign body response against the medical device, wherein the medical device is adapted to be affixed to, or implanted within, the soft tissue of an animal.



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

## METHODS AND DEVICES TO MODULATE THE WOUND RESPONSE

### BACKGROUND OF THE INVENTION

Animals exhibit a variety of physiological and biochemical responses at the site of tissue damage or injury. These physiological and biochemical responses are 5 collectively referred to as the wound response. The wound response facilitates the repair or replacement of the damaged or destroyed tissue. In some situations, however, wounded tissue exhibits a chronic wound response that adversely affects the health or well-being of the wounded animal.

The implantation of a medical device into soft tissue elicits a wound 10 response. This type of wound response is called the foreign body response and results in the encapsulation of the implant by a poorly-vascularized, collagenous, capsule that can compromise the function of the implant. In addition, the continued presence of the implant can lead to a chronic inflammatory response that is mediated, in part, by macrophages.

15 Thrombospondin-2 (TSP2) is a secreted, extracellular matrix glycoprotein with potent anti-angiogenic activity (Bornstein et al., 2000, Matrix Biology 19: 557-568). Osteopontin (OPN) is a secreted, phosphorylated glycoprotein that contains cell adhesion domains (Fisher et al., Genomics 7, 491-502 (1990)). The present inventors have discovered that modulation of the amount and/or biological activity of 20 osteopontin (OPN) and/or thrombospondin 2 (TSP2) in an animal can be utilized to

modulate the wound response, such as the foreign body response to an implanted medical device.

#### SUMMARY OF THE INVENTION

In accordance with the foregoing, in one aspect the present invention provides  
5 methods of modulating the amount and/or biological activity of thrombospondin 2 or osteopontin in an animal, the methods comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to modulate the amount and/or biological activity of thrombospondin 2 or osteopontin in the animal. In this context,  
10 when used with reference to OPN, the term "modulating" means increasing or decreasing the amount and/or biological activity of OPN. In this context, when used with reference to TSP2, the term "modulating" means decreasing the amount and/or biological activity of TSP2. In some embodiments of this aspect of the invention, the amount and/or biological activity of OPN is increased. In some embodiments of this  
15 aspect of the invention, the amount and/or biological activity of TSP2 is decreased.

In another aspect, the present invention provides methods of improving the wound response in an animal, the methods comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to improve the wound  
20 response in the animal.

In another aspect, the present invention provides methods of reducing the foreign body response in an animal, the methods comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to reduce the foreign body  
25 response in the animal. Typically, in the practice of the methods of the invention to improve the wound response, and/or to reduce the foreign body response, the amount and/or biological activity of osteopontin is increased, and/or the amount and/or biological activity of thrombospondin-2 is decreased.

The methods of the invention can be used to modulate the wound response in  
30 any situation where modulation of the wound response is desirable, including

situations in which it is desirable to reduce the foreign body response, and including situations in which it is desirable to improve the wound response.

In another aspect, the present invention provides medical devices, each medical device comprises (a) a device body; and (b) a surface layer attached to the device body, the surface layer including an amount of an agonist or antagonist of a matricellular protein sufficient to reduce the foreign body response against the medical device, wherein the device is adapted to be affixed to, or implanted within, the soft tissue of an animal. Thus, the medical devices of the invention are useful in any situation in which it is desired to reduce the foreign body response against an implanted medical device.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:

FIGURE 1 shows a perspective view of a representative medical device of the invention with a portion of the surface layer removed to expose the underlying device body.

FIGURE 2 shows a transverse cross-section of the medical device of FIGURE 1.

FIGURE 3 shows the porous matrix structure of the surface layer of the representative medical device shown in FIGURE 1.

FIGURE 4 shows a perspective view of a representative medical device of the invention that includes two surface layers disposed one upon the other. The outer surface layer includes osteopontin protein, and the inner surface layer includes an antagonist of thrombospondin 2.

FIGURE 5 shows a perspective view of a representative medical device of the invention that includes a device body, and a surface layer disposed on the device body. The surface layer includes a first area, including a first agonist or first antagonist of a matricellular protein, and a second area, including a second agonist or

second antagonist of a matricellular protein. The first agonist is different from the second agonist, and the first antagonist is different from the second antagonist.

FIGURE 6 shows data showing the extent of vascularization of foreign body capsules formed around devices implanted into mice. The devices were each made 5 from a millipore filter coated with a collagen matrix. The collagen matrices were impregnated with a plasmid including either a TSP2 sense (S), or TSP2 antisense (AS), nucleic acid molecule. P represents devices coated with a collagen matrix that was not impregnated with a plasmid. The devices were implanted into either TSP2-null (-/-) or normal control (+/+) mice. The x-axis shows the number of weeks (two 10 or four) of implantation within a mouse. The y-axis shows the number of blood vessels, per visual field, within each foreign body capsule as viewed under a microscope. "Control" represents implanted millipore filters that were not coated with collagen.

FIGURE 7 shows the number of foreign body giant cells produced at the site 15 of implantation of fixed bovine pericardium samples into either OPN null mice (OPN knockout mice) or normal control mice. The results from seven OPN null mice and seven control mice were measured. The numbers of foreign body giant cells was measured at 14 days and 30 days post implantation.

FIGURE 8A shows the foreign body capsule thickness for polyethylene discs 20 (PE), polyethylene discs coated with tetraglyme (PE glyme), and polyethylene discs coated with tetraglyme to which are covalently attached osteopontin protein molecules (PE glyme OPN). The discs were implanted into mice and the foregoing parameters measured after four weeks.

FIGURE 8B shows the macrophage score (a measure of the number of 25 macrophages in each disc) for the discs described in the legend for FIGURE 8A.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. The following definitions are provided in order to provide clarity with respect to the terms 30 as they are used in the specification and claims to describe the present invention.

As used herein, the term "wound response" refers collectively to the biochemical and physiological repair processes elicited at the site of wounding in, or on, an animal body, such as by the implantation of a medical device. The wound response is characterized by a transient inflammatory reaction followed by an  
5 invasion of collagen secreting fibroblasts and new vasculature formation in the wound bed. These events are followed by granulation tissue formation and remodeling.

The term "matricellular protein" refers to proteins that have the ability to simultaneously interact with a component of the extracellular matrix and a  
10 component of the cell surface. Some matricellular proteins can interact with growth factors and/or proteinases. Matricellular proteins function primarily to regulate cell adhesion, movement, and function. Examples of matricellular proteins include TSP1 (Chen et al., Matrix Biology 19: 597-614), TSP2 (Bornstein et al., Matrix Biology 19: 557-568) OPN (Giachelli and Steitz, Matrix Biology 19: 615-622) tenascin-C  
15 (Jones and Jones, Matrix Biology 19: 581-596) and SPARC (Brekken and Sage, Matrix Biology 19: 569-580). Each of the foregoing publications are incorporated herein by reference.

The term "foreign body response" refers to a type of wound response in which a poorly-vascularized, collagenous, capsule forms around a structure (such as  
20 a medical device) implanted into an animal body.

The phrase "soft tissue of an animal" refers to any animal tissue except bone, nail, or hair. The phrase "soft tissue of an animal" includes, for example, muscle and skin.

The term "hybridize under stringent conditions", and grammatical equivalents  
25 thereof, refers to the ability of a nucleic acid molecule to hybridize to a target nucleic acid molecule (such as a target nucleic acid molecule immobilized on a DNA or RNA blot, such as a Southern blot or Northern blot) under defined conditions of temperature and salt concentration. Typically, stringent hybridization conditions are no more than 25°C to 30°C (for example, 10°C) below the melting temperature (Tm)  
30 of the native duplex. By way of non-limiting example, representative salt and

temperature conditions for achieving stringent hybridization are: 5X SSC, at 65°C, or equivalent conditions; *see generally*, Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1987; Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing, 1987. Tm for nucleic acid molecules greater than about 100 bases can be calculated by the formula  $Tm = 81.5 + 0.41\%(G+C) - \log(Na^+)$ . For oligonucleotide molecules less than 100 bases in length, exemplary hybridization conditions are 5 to 10°C below Tm. On average, the Tm of a short oligonucleotide duplex is reduced by approximately  $(500/\text{oligonucleotide length})^\circ\text{C}$ .

10 The abbreviation "SSC" refers to a buffer used in nucleic acid hybridization solutions. One liter of the 20X (twenty times concentrate) stock SSC buffer solution (pH 7.0) contains 175.3 g sodium chloride and 88.2 g sodium citrate.

15 The term "sequence identity" or "percent identical" as applied to nucleic acid molecules is the percentage of nucleic acid residues in a candidate nucleic acid molecule sequence that are identical with a subject nucleic acid molecule sequence (such as the nucleic acid molecule sequence set forth in SEQ ID NO:1), after aligning the sequences to achieve the maximum percent identity, and not considering any nucleic acid residue substitutions as part of the sequence identity. No gaps are introduced into the candidate nucleic acid sequence in order to achieve the best 20 alignment.

Nucleic acid sequence identity can be determined in the following manner. The subject polynucleotide molecule sequence is used to search a nucleic acid sequence database, such as the Genbank database (accessible at Website <http://www.ncbi.nlm.nih.gov/blast/>), using the program BLASTN version 2.1 (based 25 on Altschul et al., Nucleic Acids Research 25: 3389-3402 (1997)). The program is used in the ungapped mode. Default filtering is used to remove sequence homologies due to regions of low complexity as defined in Wootton, J.C. and S. Federhen, Methods in Enzymology 266: 554-571 (1996). The default parameters of BLASTN are utilized.

The term "sequence identity" or "percent identical" as applied to protein molecules is the percentage of amino acid residues in a candidate protein molecule sequence that are identical with a subject protein sequence (such as the protein sequence set forth in SEQ ID NO:2), after aligning the sequences to achieve the  
5 maximum percent identity. No gaps are introduced into the candidate protein sequence in order to achieve the best alignment.

Amino acid sequence identity can be determined in the following manner. The subject protein sequence is used to search a protein sequence database, such as the GenBank database (accessible at web site <http://www.ncbi.nlm.nih.gov/blast/>),  
10 using the BLASTP program. The program is used in the ungapped mode. Default filtering is used to remove sequence homologies due to regions of low complexity. The default parameters of BLASTP are utilized. Filtering for sequences of low complexity utilize the SEG program.

The term "antibody" encompasses polyclonal and monoclonal antibody preparations, CDR-grafted antibody preparations, as well as preparations including hybrid antibodies, altered antibodies, F(AB)<sub>2</sub> fragments, F(AB) molecules, Fv fragments, single domain antibodies, chimeric antibodies and functional fragments thereof which exhibit immunological binding properties of the parent antibody molecule. The antibodies can also be humanized.  
15

In one aspect, the present invention provides methods of modulating the amount and/or biological activity of thrombospondin 2 (TSP2) and/or osteopontin (OPN) in an animal. The methods of this aspect of the invention comprise the step of introducing into the animal an amount of a molecule, selected from the group consisting of OPN and a TSP2 antagonist, effective to modulate the amount and/or  
20 biological activity of TSP2 or OPN in the animal. In this context, when used with reference to OPN, the term "modulating" means increasing or decreasing the amount and/or biological activity of OPN. In this context, when used with reference to TSP2, the term "modulating" means decreasing the amount and/or biological activity of TSP2. In some embodiments of this aspect of the invention, the amount and/or  
25 biological activity of OPN is increased. In some embodiments of this aspect of the  
30

invention, the amount and/or biological activity of TSP2 is decreased. The methods described in the present invention are applicable to any animal, including mammals, such as human beings. The methods of this aspect of the invention can be used to modulate the wound response in any situation where modulation of the wound  
5 response is desirable, including situations in which it is desirable to reduce the foreign body response and including situations in which it is desirable to improve the wound response (e.g. improve the rate of wound healing at the site of a cut, abrasion, or burn to soft tissue). In some embodiments, in order to modulate the wound response, the amount and/or biological activity of OPN is increased, and/or the  
10 amount and/or biological activity of TSP2 is decreased.

The methods of this aspect of the invention can be used, for example, to improve the wound response (e.g., by increasing the magnitude of one or more of the biochemical and/or physiological and/or physical responses that make up the wound response, and/or reducing the duration of the wound response), such as at the site of a  
15 cut, abrasion or burn (e.g. by applying to the cut, abrasion or burn, an article, such as an adhesive strip, that includes an amount of OPN and/or a TSP2 antagonist, that is effective to improve the wound response). Improved wound response is especially important, for example, in a diabetic person, where cuts, abrasions and burns are slow to heal.

20 The methods of this aspect of the invention can also be used, for example, to reduce the foreign body response, (e.g. by reducing the magnitude of one or more of the biochemical and/or physiological and/or physical responses that make up the foreign body response, and/or reducing the duration of the foreign body response). Representative examples of situations in which it is desirable to reduce the foreign  
25 body response include the reduction of the foreign body response against an implanted medical device, thereby prolonging the working lifetime of the implanted device.

Other examples of situations where it is desirable to use the methods of the invention to reduce the foreign body response include: reduction of the foreign body  
30 response at the site of an implanted vascular stent, thereby preventing or delaying

restenosis at the location of the stent; and reduction of the foreign body response elicited by tissues or organs implanted into an animal body, thereby promoting the acceptance of the implanted tissue or organ by the host body.

A reduction in the foreign body response is characterized by at least one of  
5 the following changes in a component of the foreign body response that occurs as a result of treatment of animal tissue in accordance with the methods of the invention: a decrease in the amount of fibrosis (measured, for example, by a decrease in hydroxy-proline content which indicates the level of collagen in the foreign body capsule); a decrease in the amount of inflammation (measured, for example, by  
10 counting the number of inflammatory cells, and the number of foreign body giant cells, in histological sections; or measuring the levels of cytokines, such as interleukin and monocyte chemoattractant protein, in wound extracts by ELISA); an increase in the amount of vascularization of the capsule formed as part of the foreign body response (measured, for example, by visualizing blood vessels in histological  
15 sections with anti-PECAM1 antibody and the peroxidase reaction; the number of vessels and their average size are estimated with imaging software such as Metamorph); an increase in the amount of permeability of the capsule formed as part of the foreign body response (measured, for example, as the release of traceable chemicals from implanted devices, or ability of implanted sensors to sense plasma  
20 levels of molecules such as glucose); a decrease in the amount of the capsule formed around the foreign body (capsule thickness can be measured from histological sections with the aid of ocular micrometers); and a decrease in the amount of contraction of collagen fibers within the capsule that is formed as part of the foreign body response (measured as tensile strength of the capsule or induced shape change  
25 on malleable implants). The decrease, or increase, of any of the foregoing parameters can be a decrease, or increase, relative to the amount of the parameter present before treatment in accordance with the methods of the invention; or a decrease, or increase, relative to the amount of the parameter present in control tissue that is not treated in accordance with the methods of the present invention.

Thus, in one aspect, the present invention provides methods of improving the wound response in an animal, the methods comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to improve the wound 5 response in the animal. In another aspect, the present invention provides methods of reducing the foreign body response in an animal, the methods comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to reduce the foreign body response in the animal. Typically, in the practice of the methods of the 10 invention to improve the wound response, and/or to reduce the foreign body response, the amount and/or biological activity of osteopontin is increased, and/or the amount and/or biological activity of thrombospondin-2 is decreased.

Any OPN protein that improves the wound response and/or reduces the foreign body response is useful in the practice of the present invention. OPN 15 proteins useful in the methods of the present invention include naturally purified OPN protein (which may be chemically modified after purification), chemically synthesized OPN protein, and OPN protein produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, insect, mammalian, avian and higher plant cells.

OPN fragments that improve the wound response and/or reduce the foreign 20 body response are also useful in the practice of the present invention. Also, modified OPN proteins, or fragments thereof, that improve the wound response and/or reduce the foreign body response are useful in the practice of the present invention. Modifications can include those that are introduced during or after translation, (e.g., 25 by glycosylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand). Modifications also include N-terminal modifications, which result from expression in a particular recombinant host, such as, for example, N-terminal methylation which occurs in certain bacterial (e.g. E. coli) expression systems. Modifications also include mutants in which amino acid substitutions are made.

OPN protein, or OPN fragments, can be recovered and purified by any applicable purification method, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, gel filtration, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and high performance liquid chromatography ("HPLC").

The cDNA molecule set forth in SEQ ID NO:1 encodes a representative example of OPN (consisting of the amino acid sequence set forth in SEQ ID NO: 2) useful in the practice of the invention. Other representative examples of useful OPN proteins include OPN proteins that are at least 70% identical to the OPN protein set forth in SEQ ID NO. 2.

The amount and/or biological activity of OPN in an animal can be modulated (for example increased) by any suitable method, such as one or more of the following, representative, methods: the delivery of nucleic acid molecules encoding OPN into the body of an animal; increasing the level of endogenous OPN transcription and/or translation within the body of an animal; delivery of OPN protein (or OPN fragments that retain the ability to modulate the wound response) into the body of an animal by implanting into the body of an animal, or attaching to the body of an animal, a structure comprising OPN, or OPN peptides retaining the ability to modulate the wound response, disposed on a surface of the structure that contacts tissue of the animal body when the structure is implanted therein.

OPN protein, or OPN peptides retaining the ability to modulate the wound response, can be delivered into the body of an animal by any suitable means. By way of representative example, OPN protein, or fragments thereto, can be introduced into an animal body by application to a bodily membrane capable of absorbing the protein, for example the nasal, gastrointestinal and rectal membranes. The protein is typically applied to the absorptive membrane in conjunction with a permeation enhancer. (See, e.g., V.H.L. Lee, *Crit. Rev. Ther. Drug Carrier Syst.*, 5:69 (1988); V.H.L. Lee, *J. Controlled Release*, 13:213 (1990); V.H.L. Lee, Ed., *Peptide and Protein Drug Delivery*, Marcel Dekker, New York (1991); A.G. DeBoer et al., *J. Controlled Release*, 13:241 (1990)). For example, STDHF is a synthetic

derivative of fusidic acid, a steroidal surfactant that is similar in structure to the bile salts, and has been used as a permeation enhancer for nasal delivery. (W.A. Lee, *Biopharm.* Nov./Dec., 22, 1990).

The OPN protein, or fragments thereof, may be introduced in association with  
5 another molecule, such as a lipid, to protect the protein from enzymatic degradation. For example, the covalent attachment of polymers, especially polyethylene glycol (PEG), has been used to protect certain proteins from enzymatic hydrolysis in the body and thus prolong half-life (F. Fuertges, et al., *J. Controlled Release*, **11**:139 (1990)). Many polymer systems have been reported for protein delivery (Y.H. Bae,  
10 et al., *J. Controlled Release*, **9**:271 (1989); R. Hori, et al., *Pharm. Res.*, **6**:813 (1989); I. Yamakawa, et al., *J. Pharm. Sci.*, **79**:505 (1990); I. Yoshihiro, et al., *J. Controlled Release*, **10**:195 (1989); M. Asano, et al., *J. Controlled Release*, **9**:111 (1989); J. Rosenblatt et al., *J. Controlled Release*, **9**:195 (1989); K. Makino, *J. Controlled Release*, **12**:235 (1990); Y. Takakura et al., *J. Pharm. Sci.*, **78**:117 (1989);  
15 Y. Takakura et al., *J. Pharm. Sci.*, **78**:219 (1989)).

For transdermal applications, the OPN protein, or fragments thereof, may be combined with other suitable ingredients, such as carriers and/or adjuvants. There are no limitations on the nature of such other ingredients, except that they must be pharmaceutically acceptable and efficacious for their intended administration, and  
20 cannot degrade the activity of the active ingredients of the composition. Examples of suitable vehicles include ointments, creams, gels, or suspensions, with or without purified collagen. The OPN protein, or fragments thereof, also may be impregnated into transdermal patches, plasters, and bandages, preferably in liquid or semi-liquid form.

25 The amount and/or biological activity of OPN in an animal can be increased, for example, by delivery of nucleic acid molecules encoding OPN, or a biologically active fragment thereof, into the body of an animal. By way of example, a vector which includes a nucleic acid molecule (typically a DNA molecule) that encodes an OPN protein can be introduced into any suitable host cell, including animal and  
30 human cells, and the encoded OPN protein expressed therein. The vector can be

introduced into host cells *in vitro*, and the modified cells introduced into the body of an animal, or the vector can be introduced into cells, *in vivo*, within the body of an animal. Any art-recognized gene delivery method can be used to introduce a vector into one or more cells for expression therein, including: transduction, transfection,  
5 transformation, direct injection, electroporation, virus-mediated gene delivery, amino acid-mediated gene delivery, biolistic gene delivery, lipofection and heat shock. See, generally, Sambrook et al, *supra*. Representative, non-viral, methods of gene delivery into cells are disclosed in Huang, L., Hung, M-C, and Wagner, E., Non-Viral Vectors for Gene Therapy, Academic Press, San Diego, California (1999).

10 Expression vectors useful for expressing OPN protein, or biologically active fragments thereof, include chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, bacteriophages, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and  
15 vectors derived from combinations thereof, such as cosmids and phagemids. In certain embodiments in this regard, the vectors provide for specific expression, which may be inducible and/or cell type-specific. Among such expression vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.

20 For example, a coding sequence for OPN, or a biologically active fragment thereof, can be introduced into cells *in situ*, or after removal of the cells from the body, by means of viral vectors. For example, retroviruses are RNA viruses that have the ability to insert their genes into host cell chromosomes after infection. Retroviral vectors have been developed that lack the genes encoding viral proteins,  
25 but retain the ability to infect cells and insert their genes into the chromosomes of the target cell (A.D. Miller, *Hum. Gen. Ther.* 1:5-14 (1990)). Adenoviral vectors are designed to be administered directly to patients. Unlike retroviral vectors, adenoviral vectors do not integrate into the chromosome of the host cell. Instead, genes introduced into cells using adenoviral vectors are maintained in the nucleus as an  
30 extrachromosomal element (episome) that persists for a limited time period.

Adenoviral vectors will infect dividing and non-dividing cells in many different tissues *in vivo* including airway epithelial cells, endothelial cells, hepatocytes and various tumors (B.C. Trapnell, *Adv Drug Del Rev.* **12**:185-199 (1993)).

Another viral vector is the herpes simplex virus; a large, double-stranded DNA virus. Recombinant forms of the vaccinia virus can accommodate large inserts and are generated by homologous recombination. To date, this vector has been used to deliver, for example, interleukins (ILs), such as human IL-1 $\beta$  and the costimulatory molecules B7-1 and B7-2 (G.R. Peplinski et al., *Ann. Surg. Oncol.* **2**:151-9 (1995); J.W. Hodge et al., *Cancer Res.* **54**:5552-55 (1994)).

A plasmid vector can be introduced into mammalian cells in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid (e.g., LIPOFECTAMINE™; Life Technologies, Inc.; Rockville, Md.) or in a complex with a virus (such as an adenovirus) or components of a virus (such as viral capsid peptides). If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

For example, a vector may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, or a gene activated collagen matrix. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers.

Recently, liposomes were developed with improved serum stability and circulation half-times (see, e.g., U.S. Pat. No. 5,741,516). Furthermore, various methods of liposome and liposome-like preparations as potential drug carriers have been reviewed (see, e.g., U.S. Pat. No. 5,567,434; U.S. Pat. No. 5,552,157; U.S. Pat. No. 5,565,213; U.S. Pat. No. 5,738,868 and U.S. Pat. No. 5,795,587).

Additionally, studies have demonstrated that intramuscular injection of plasmid DNA formulated with 5% PVP (50,000 kDa) increases the level of reporter

gene expression in muscle as much as 200-fold over the levels found with injection of DNA in saline alone (R.J. Mumper et al., *Pharm. Res.* **13**:701-709 (1996); R.J. Mumper et al., *Proc. Intern. Symp. Cont. Rol. Bioac. Mater.* **22**:325-326 (1995)). Intramuscular administration of plasmid DNA results in gene expression that lasts for 5 many months (J.A. Wolff et al., *Hum. Mol. Genet.* **1**:363-369 (1992); M. Manthorpe et al., *Hum. Gene Ther.* **4**:419-431 (1993); G. Ascadi et al., *New Biol.* **3**:71-81 (1991), D. Gal et al., *Lab. Invest.* **68**:18-25 (1993)).

Various devices have been developed for enhancing the availability of DNA to a target cell. A simple approach is to contact the target cell physically with 10 catheters or implantable materials containing DNA (G.D. Chapman et al., *Circulation Res.* **71**:27-33 (1992)). Another method for achieving gene transfer involves using a fibrous collagen implant material soaked in a solution of DNA shortly before being placed in the site in which one desires to achieve gene transfer. The matrix may become impregnated with a gene DNA segment simply by soaking 15 the matrix in a solution containing the DNA, such as a plasmid solution.

Another approach is to utilize needle-free, jet injection devices which project a column of liquid directly into the target tissue under high pressure. (P.A. Furth et al., *Anal. Biochem.* **20**:365-368 (1992); (H.L. Vahlsing et al., *J. Immunol. Meth.* **175**:11-22 (1994); (F.D. Ledley et al., *Cell Biochem.* **18A**:226 (1994)).

20 Another device for gene delivery is the "gene gun" or Biolistic<sup>TM</sup>, a ballistic device that projects DNA-coated micro-particles directly into the nucleus of cells *in vivo*. Once within the nucleus, the DNA dissolves from the gold or tungsten microparticle and can be expressed by the target cell. This method has been used effectively to transfer genes directly into the skin, liver and muscle (N.S. Yang et al., 25 *Proc. Natl. Acad. Sci.* **87**:9568-9572 (1990); L. Cheng et al., *Proc. Natl. Acad. Sci. USA.* **90**:4455-4459 (1993); R.S. Williams et al., *Proc. Natl. Acad. Sci.* **88**:2726-2730 (1991)).

OPN proteins, or fragments thereof, may be immobilized onto (or within) a surface of an implantable or attachable medical device. The modified surface will 30 typically be in contact with living tissue after implantation into an animal body. By

"implantable or attachable medical device" is intended any device that is implanted into, or attached to, tissue of an animal body, during the normal operation of the device (e.g., implantable drug delivery devices). Such implantable or attachable medical devices can be made from, for example, nitrocellulose, diazocellulose, glass, 5 polystyrene, polyvinylchloride, polypropylene, polyethylene, dextran, Sepharose, agar, starch, and nylon. Linkage of the protein to a device can be accomplished by any technique that does not destroy the biological activity of the linked protein, for example by attaching one or both ends of the protein to the device. Attachment may also be made at one or more internal sites in the protein. Multiple attachments (both 10 internal and at the ends of the protein) may also be used. A surface of an implantable or attachable medical device can be modified to include functional groups (e.g., carboxyl, amide, amino, ether, hydroxyl, cyano, nitrido, sulfanamido, acetylinic, epoxide, silanic, anhydric, succinimic, azido) for protein immobilization thereto. Coupling chemistries include, but are not limited to, the formation of esters, ethers, 15 amides, azido and sulfanamido derivatives, cyanate and other linkages to the functional groups available on OPN proteins or fragments. OPN protein, or fragments thereof, can also be attached non-covalently by the addition of an affinity tag sequence to the protein, such as GST (Smith, D. B., and Johnson, K. S., Gene 67:31 (1988)), polyhistidines (Hochuli, E., et al., J. Chromatog. 411:77 (1987)), or 20 biotin. Such affinity tags may be used for the reversible attachment of the protein to a device. The medical devices of the invention described herein can be used to deliver OPN proteins, or fragments thereof, to an animal body.

Methods of delivery of OPN proteins, or fragments thereof, also include administration by oral, pulmonary, parenteral (e.g., intramuscular, intraperitoneal, 25 intravenous (IV) or subcutaneous injection), inhalation (such as via a fine powder formulation), transdermal, nasal, vaginal, rectal, or sublingual routes of administration, and can be formulated in dosage forms appropriate for each route of administration.

In another embodiment of the methods of the present invention, the amount 30 and/or biological activity of thrombospondin 2 (TSP2) is decreased in an animal by a

method comprising the step of introducing into the animal an amount of a TSP2 antagonist effective to decrease the amount and/or biological activity of TSP2 in the animal. In the practice of this aspect of the invention, representative TSP2 antagonists include: TSP2 antisense nucleic acid molecules (such as antisense mRNA, antisense DNA or antisense oligonucleotides), TSP2 ribozymes, and molecules that inhibit the biological activity of TSP2 (such as anti-TSP2 antibodies, or a blocking peptide which interacts with TSP2 or a TSP2 receptor), thereby preventing TSP2 from eliciting a biological response. The methods of this aspect of the invention can be used to improve the wound response in an animal, and/or reduce 10 the foreign body response in an animal.

An antisense nucleic acid molecule may be constructed in a number of different ways provided that it is capable of interfering with the expression of a target gene. For example, an antisense nucleic acid molecule can be constructed by inverting the coding region (or a portion thereof) of TSP2 relative to its normal 15 orientation for transcription to allow the transcription of its complement.

The antisense nucleic acid molecule is usually substantially identical to at least a portion of the target gene or genes. The nucleic acid, however, need not be perfectly identical to inhibit expression. Generally, higher homology can be used to compensate for the use of a shorter antisense nucleic acid molecule. The minimal 20 percent identity is typically greater than about 65%, but a higher percent identity may exert a more effective repression of expression of the endogenous sequence. Substantially greater percent identity of more than about 80% typically is preferred, though about 95% to absolute identity is typically most preferred.

The antisense nucleic acid molecule need not have the same intron or exon 25 pattern as the target gene, and non-coding segments of the target gene may be equally effective in achieving antisense suppression of target gene expression as coding segments. A DNA sequence of at least about 30 or 40 nucleotides may be used as the antisense nucleic acid molecule, although a longer sequence is preferable. In the present invention, a representative example of a useful antagonist of TSP2 is an 30 antisense TSP2 nucleic acid molecule which is at least ninety percent identical to the

complement of the TSP2 cDNA consisting of the nucleic acid sequence set forth in SEQ ID NO: 3. The nucleic acid sequence set forth in SEQ ID NO: 3 encodes the TSP2 protein consisting of the amino acid sequence set forth in SEQ ID NO: 4.

The targeting of antisense oligonucleotides to bind TSP2 mRNA is another 5 mechanism that may be used to reduce the level of TSP2 protein synthesis. For example, the synthesis of polygalacturonase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U.S. Pat. No. 5,739,119 and U.S. Pat. No. 5,759,829). Furthermore, examples of antisense inhibition have been demonstrated with the 10 nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA<sub>A</sub> receptor and human EGF (*see, e.g.*, U.S. Pat. No. 5,801,154; U.S. Pat. No. 5,789,573; U.S. Pat. No. 5,718,709 and U.S. Pat. No. 5,610,288).

Ribozymes can also be utilized to decrease the amount and/or biological 15 activity of TSP2, such as ribozymes which target TSP2 mRNA. Ribozymes are catalytic RNA molecules that can cleave nucleic acid molecules having a sequence that is completely or partially homologous to the sequence of the ribozyme. It is possible to design ribozyme transgenes that encode RNA ribozymes that specifically pair with a target RNA and cleave the phosphodiester backbone at a specific location, 20 thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the antisense constructs.

25 Ribozymes useful in the practice of the invention typically comprise a hybridizing region, of at least about nine nucleotides, which is complementary in nucleotide sequence to at least part of the target TSP2 mRNA, and a catalytic region which is adapted to cleave the target TSP2 mRNA (*see generally*, EPA No. 0 321 201; WO88/04300; Haseloff & Gerlach, *Nature* 334:585-591 [1988]; Fedor &

Uhlenbeck, *Proc. Natl. Acad. Sci.: USA* 87:1668-1672 [1990]; Cech & Bass, *Ann. Rev. Biochem.* 55:599-629 [1986]).

Representative methods of delivery for antisense TSP2 molecules, and/or TSP2 ribozymes, include any of the methods of delivering nucleic acid molecules  
5 into living cells described in this patent application.

In another embodiment of this aspect of the present invention, the TSP2 antagonist is an anti-TSP2 antibody. By way of representative example, antigen useful for raising antibodies can be prepared in the following manner. A nucleic acid molecule (such as a TSP2 cDNA molecule) is cloned into a plasmid vector, such as a  
10 Bluescript plasmid (available from Stratagene, Inc., La Jolla, California). The recombinant vector is then introduced into an *E. coli* strain (such as *E. coli* XL1-Blue, also available from Stratagene, Inc.) and the polypeptide encoded by the nucleic acid molecule is expressed in *E. coli* and then purified. Alternatively, polypeptides can be prepared using peptide synthesis methods that are well known in  
15 the art. The synthetic polypeptides can then be used to prepare antibodies. Direct peptide synthesis using solid-phase techniques (Stewart et al., *Solid-Phase Peptide Synthesis*, W H Freeman Co, San Francisco Calif. (1969); Merrifield, *J. Am. Chem. Soc.* 85:2149-2154 (1963) is an alternative to recombinant or chimeric peptide production. Automated synthesis may be achieved, for example, using Applied  
20 Biosystems 431A Peptide Synthesizer (Foster City, Calif.) in accordance with the instructions provided by the manufacturer. Methods for preparing monoclonal and polyclonal antibodies are well known to those of ordinary skill in the art and are set forth, for example, in chapters five and six of *Antibodies A Laboratory Manual*, E. Harlow and D. Lane, Cold Spring Harbor Laboratory (1988). Antibody production  
25 includes not only the stimulation of an immune response by injection into animals, but also analogous processes such as the production of synthetic antibodies, the screening of recombinant immunoglobulin libraries for specific-binding molecules (Orlandi et al., *Proc. Natl. Acad. Sci. USA* 86:3833, 1989, or Huse et al. *Science* 256:1275, 1989), or the *in vitro* stimulation of lymphocyte populations.

The invention also extends to non-antibody polypeptides, sometimes referred to as blocking peptides, that have been designed to bind specifically to, and inhibit the active site of, TSP2, or a TSP2 binding partner, or a receptor of TSP2. For example, the domain of TSP2 which binds to the receptor CD36 can be targeted with 5 a blocking peptide. Other examples of the design of such peptides, which possess a prescribed ligand specificity are given in Beste et al. (1999, Proceedings of the National Academy of Science 96:1898-1903).

An additional strategy suitable for suppression of target gene activity entails the sense expression of a mutated or partially deleted form of the protein encoded by 10 the target gene according to general criteria for the production of dominant negative mutations (Herskowitz I, *Nature* 329: 219-222 (1987)).

Representative methods of delivery for anti-TSP2 antibodies and/or blocking peptides include any of the protein delivery methods disclosed in this patent application.

15 In another aspect, the present invention provides medical devices comprising (a) a device body; and (b) a surface layer attached to the device body, the surface layer including an amount of an agonist or antagonist of a matricellular protein sufficient to reduce the foreign body response against the medical device, wherein the device is adapted to be affixed to, or implanted within, the soft tissue of an 20 animal.

Some medical devices of the invention are adapted to be implanted into the soft tissue of an animal, such as a mammal, including a human, during the normal operation of the medical device. Implantable medical devices of the invention may be completely implanted into the soft tissue of an animal body (*i.e.*, the entire device 25 is implanted within the body), or the device may be partially implanted into an animal body (*i.e.*, only part of the device is implanted within an animal body, the remainder of the device being located outside of the animal body). Representative examples of completely implantable medical devices include, but are not limited to: cardiovascular devices (such as vascular grafts and stents), artificial blood vessels, 30 artificial bone joints, such as hip joints, and scaffolds that support tissue growth (in

such anatomical structures as nerves, pancreas, eye and muscle). Representative examples of partially implantable medical devices include: biosensors (such as those used to monitor the level of drugs within a living body, or the level of blood glucose in a diabetic patient) and percutaneous devices (such as catheters) that penetrate the  
5 skin and link a living body to a medical device, such as a kidney dialysis machine.

Some medical devices of the invention are adapted to be affixed to soft tissue of an animal, such as a mammal, including a human, during the normal operation of the medical device. These medical devices are typically affixed to the skin of an animal body. Examples of medical devices that are adapted to be affixed to soft  
10 tissue of an animal include skin substitutes, and wound or burn treatment devices (such as surgical bandages, transdermal patches and hydrogels).

The device body can be made from any suitable material. Representative examples of synthetic polymers useful for making the device body include: (poly)urethane, (poly)carbonate, (poly)ethylene, (poly)propylene, (poly)lactic acid,  
15 (poly)galactic acid, (poly)acrylamide, (poly)methyl methacrylate and (poly)styrene. Useful natural polymers include collagen, hyaluronic acid and elastin.

The surface layer can cover the whole of the device body, or one or more parts of the device body, such as areas of the device body where it is desired to reduce the foreign body response. The surface layer can be made, for example, from  
20 any suitable material that: (a) permits deposition therein, or attachment thereto, of an amount of an agonist, or antagonist, of a matricellular protein sufficient to reduce the foreign body response against the medical device; and (b) can be attached to the device body (before or after deposition within, or attachment to, the surface layer of an amount of an agonist, or antagonist, of a matricellular protein sufficient to reduce  
25 the foreign body response against the medical device). Representative examples of materials useful for making the surface layer include porous matrices. Porous matrices are useful, for example, for delivering antisense TSP2 molecules to an animal body.

Representative porous matrices useful for making the surface layer are those  
30 prepared from tendon or dermal collagen, as may be obtained from a variety of

commercial sources, (e.g., Sigma and Collagen Corporation), or collagen matrices prepared as described in U.S. Pat. Nos. 4,394,370 and 4,975,527. One collagenous material is termed UltraFiber<sup>TM</sup>, and is obtainable from Norian Corp. (Mountain View, Calif.).

5        Certain polymeric matrices may also be employed if desired, these include acrylic ester polymers and lactic acid polymers, as disclosed, for example, in U.S. Pat. Nos. 4,526,909, and 4,563,489. Particular examples of useful polymers are those of orthoesters, anhydrides, propylene-cofumarates, or a polymer of one or more α-hydroxy carboxylic acid monomers, (e.g. α-hydroxy acetic acid (glycolic acid) 10 and/or α-hydroxy propionic acid (lactic acid).

The surface layer can be made, for example, by attachment of matricellular protein(s) to the device body, for example by covalent activation of the surface of the medical device. By way of representative example, matricellular protein(s) can be attached to the device body by any of the following pairs of reactive groups (one 15 member of the pair being present on the surface of the device body, and the other member of the pair being present on the matricellular protein(s): hydroxyl/carboxylic acid to yield an ester linkage; hydroxyl/anhydride to yield an ester linkage; hydroxyl/isocyanate to yield a urethane linkage.

A surface of a device body that does not possess useful reactive groups can be 20 treated with radio-frequency discharge plasma (RFGD) etching to generate reactive groups in order to allow deposition of matricellular protein(s) (e.g., treatment with oxygen plasma to introduce oxygen-containing groups; treatment with propyl amino plasma to introduce amine groups). When an RFGD glow discharge plasma is created using an organic vapor, deposition of a polymeric overlayer occurs on the 25 exposed surface. RFGD plasma deposited films offer several unique advantages. They are smooth, conformal, and uniform. Film thickness is easily controlled and ultrathin films (10-1000 Angstroms) are readily achieved, allowing for surface modification of a material without alteration to its bulk properties. Moreover, plasma films are highly-crosslinked and pin-hole free, and therefore chemically stable and 30 mechanically durable. RFGD plasma deposition of organic thin films has been used

in microelectronic fabrication, adhesion promotion, corrosion protection, permeation control, as well as biomaterials. (see, e.g., Ratner, US Pat No 6,131,580).

An amount of an agonist or antagonist of a matricellular protein sufficient to reduce the foreign body response to the implanted medical device is included in or on a surface layer of the medical device. Agonists or antagonists of a matricellular protein include, for example: proteins, peptides, antibodies, and nucleic acid molecules. Useful, representative, examples of TSP2 antagonists include: TSP2 antisense nucleic acid molecules (such as antisense mRNA, antisense DNA or antisense oligonucleotides), TSP2 ribozymes, and molecules that inhibit the biological activity of TSP2 (such as anti-TSP2 antibodies, or a blocking peptide which interacts with TSP2 or a TSP2 receptor), thereby preventing TSP2 from eliciting a biological response. OPN, or OPN fragments retaining the ability to reduce the foreign body response, can be included in the surface layer of the medical device. Any combination of agonists and/or antagonists of a matricellular protein can be included in or on a surface layer of a medical device of the invention.

FIGURE 1 shows a representative medical device 10 of the present invention, in the form of an implantable drug delivery device, which includes a device body 12 to which is attached a surface layer 14. In the embodiment shown in FIGURE 1, surface layer 14 has been partially removed to show device body 12 beneath. Device body 12 is indicated by hatching. As shown in the cross-sectional view of medical device 10 in FIGURE 2, surface layer 14 includes a surface layer body 16 that defines an internal surface 18, attached to device body 12, and an external surface 20.

In the representative embodiment of device 10 shown in FIGURES 1 and 2, surface layer 14 is made from a porous matrix. FIGURE 3 shows a representation of porous matrix 22 within which are disposed molecules 24 of an agonist or antagonist of a matricellular protein (other molecules, such as drugs, may also be disposed within porous matrix 22). Thus, in operation, device 10 is implanted into the soft tissue of an animal body where molecules 24 are released over time and reduce the foreign body response by the animal body against implanted device 10.

Some medical devices 10 of the invention include a multiplicity of surface layers 14 disposed one upon the other, wherein at least one of surface layers 14 includes an agonist or antagonist of a matricellular protein. A "multiplicity" is defined as at least two surface layers 14, and each surface layer 14 may be made 5 from the same material as the other surface layer(s) 14, or from a different material. By way of representative example, FIGURE 4 shows a medical device 10 of the invention, in the form of an implantable drug delivery device, that includes a first surface layer 14' disposed upon a second surface layer 14". First surface layer 14' includes molecules of osteopontin 26 disposed therein. Second surface layer 14" 10 includes molecules of a thrombospondin 2 antagonist 28 disposed therein. First surface layer 14' is located externally to second surface layer 14" in that first surface layer 14' is located further from device body 12 than second surface layer 14", and first surface layer 14' defines an external surface 30 of medical device 10. Thus, when implanted into an animal body, the embodiment of medical device 10 shown in 15 FIGURE 4 first releases osteopontin 26 into the surrounding tissue, then releases thrombospondin 2 antagonist 28 into the surrounding tissue.

FIGURE 5 shows a representative embodiment of a medical device 10 of the invention, in the form of a drug delivery device, that includes a device body 12 and a surface layer 14 disposed on device body 12. Surface layer 14 includes a first area 20 32, including a first agonist or first antagonist of a matricellular protein, and a second area 34, including a second agonist or second antagonist of a matricellular protein. The first agonist is different from the second agonist, and the first antagonist is different from the second antagonist. Thus, for example, first area 32 can include osteopontin protein, or nucleic acid molecules encoding osteopontin, and second area 25 34 can include a TSP2 antagonist 28, such as a TSP2 antisense nucleic acid molecule, an immobilized anti-TSP2 antibody, or an anti-TSP2 blocking peptide.

One of ordinary skill in the art will appreciate that surface layers 14 can be configured and arranged to optimize the timing of the delivery of one or more agonists and/or antagonists of a matricellular protein in order to reduce the foreign 30 body response. For example, typically antisense TSP2 molecules are not fixedly

attached to, or within, surface layer 14 so that the antisense TSP2 molecules are free to diffuse out of surface layer 14 and be taken up by the cells of surrounding tissue. Typically, however, osteopontin protein is fixedly attached, such as by covalent linkage, to, or within, surface layer 14 to prevent movement of the protein away from  
5 the wound site. It is understood by one of ordinary skill in the art that any combination of agonist and/or antagonist of one or more matricellular proteins may be included in surface layer 14.

The following examples merely illustrate the best mode now contemplated for practicing the invention, but should not be construed to limit the invention. All  
10 literature citations herein are expressly incorporated by reference.

#### Example 1

This example describes the increase in blood vessel density that occurs within a foreign body capsule as a result of the presence of a TSP2 antisense cDNA molecule in the surface layer of an implanted device.

15 Construction of plasmids: Sense and antisense TSP2 expression plasmids were generated by ligation of a 3.5-kb EcoR1 fragment of mouse TSP2 (mTSP2) cDNA into the mammalian expression vector pZeoSV (Invitrogen, San Diego, CA). The size and orientation of inserts were confirmed by restriction digestion with Xho1.

20 Generation of TSP2-null mice: These mice were generated as described (Kyriakides et al., 1998, J. Cell Biol. 140: 419-430).

Preparation of devices: The devices were each made from a millipore filter coated with a collagen matrix. The collagen matrices were impregnated with a plasmid including either a TSP2 sense, or TSP2 antisense, nucleic acid molecule.  
25 Some collagen matrices were not impregnated with a plasmid. Equal amounts (1 mg) of neutralized collagen and plasmid DNA were mixed at 4°C. Implants were bathed in this solution, placed at -70° C and then lyophilized to generate a dry gene activated matrix.

30 Implantation of devices: the devices were implanted into TSP2-null mice, and into control mice, for a 2-4 week period.

Measurement of capsule neovascularization: At 2-4 weeks post implant, the number of blood vessels per visual field was measured in the capsules surrounding the implant. Histological sections were stained with antibodies to PECAM-1 and visualized with the peroxidase reaction. The number and size of blood vessels was 5 determined from microscopic digital images collected at 400x magnification and analyzed by imaging software.

As shown in FIGURE 6, foreign body capsules formed around uncoated filters implanted into TSP2-null animals displayed an increase in blood vessel density as compared to the wild type animals treated similarly. This demonstrates that in the 10 absence of TSP2, there is an increase in neovascularization of the foreign body capsule surrounding an implant.

Under conditions designed to test TSP2 complementation, TSP2 null animals were implanted with devices comprising a millipore filter coated with a collagen matrix impregnated with a plasmid including a TSP2 cDNA in sense orientation. As 15 shown in FIGURE 6, the addition of the sense TSP2 construct led to a reduction in the vessel density within the foreign body capsule, similar to that seen in the wild-type mice, while the antisense TSP2 construct did not change the vessel density in the TSP2 null mice.

Wild-type animals implanted with a device including a surface collagen layer 20 including an antisense TSP2 construct displayed an increase in foreign body capsule blood vessel density, while no change was observed in wild-type animals implanted with a device including a sense TSP2 construct. These results were especially significant in light of the overall reduction in vascularity observed in controls in which the collagen matrix alone was coated onto the millipore filters.

25 The results above suggest that *in vivo* delivery of TSP2 antisense cDNA via a medical device of the invention can eliminate the anti-angiogenic activity of TSP2 and thereby promote vascularization of the foreign body capsule surrounding an implanted medical device.

This example shows that OPN-null mice demonstrate high levels of foreign body giant cells surrounding an implant as compared to wild type mice.

One of the hallmarks of the foreign body response is the appearance of foreign body giant cells or macrophages that have fused together as a result of 5 encountering an implanted foreign material. As many as one hundred cells fuse to form a syncytium containing as many as one hundred nuclei. In order to address the role of OPN in the foreign body response, OPN null mice (knockout mice) and normal control mice were implanted with fixed bovine pericardium and analyzed at 14 days and 30 days post implant for the appearance of foreign body giant cells.

10 Generation of OPN null mice: The mice utilized in these experiments are described in Liaw, L. et al., J. Clin Invest, 1998 **101**(7):1468-78, which publication is incorporated herein by reference.

15 Preparation of bovine pericardium implant samples: Glutaraldehyde-fixed bovine pericardial tissues were a gift from Edwards Lifesciences. Bovine pericardial tissues were excised, fixed and stored in 0.6% glutaraldehyde, pH 7.0, until use.

20 Method of implantation: 4 mm<sup>2</sup> biopsy punches of glutaraldehyde-fixed aortic valve leaflets (GFAV) were prepared, washed extensively in sterile PBS, and subcutaneously implanted into the dorsal side of anaesthetized 5-6 week old, female OPN +/+ or -/- mice (two GFAV per mouse). At the indicated times, mice were euthanized, and implants removed for histological analysis. All protocols were 25 approved by the animal use committee, University of Washington.

Foreign body giant cell formation: The OPN null mice and control mice were analyzed at 14 days and 30 days post implant for the appearance of foreign body giant cells. As shown in FIGURE 7, at both 14 days and 30 days post-implantation, the OPN null mice had higher levels of foreign body giant cells than the control mice. These results suggest that increasing the amount and/or biological activity of 25 OPN will decrease the number of foreign body giant cells and thereby reduce the foreign body reaction to an implant.

This example shows that OPN immobilized in the surface layer of an implanted device causes a reduction in both fibrous capsule thickness and the amount of macrophage infiltration of the fibrous capsule surrounding the implanted device.

Preparation of polyethylene discs: some polyethylene discs were uncoated 5 while others were coated with a non-fouling RFGD tetraglyme coating. Some tetraglyme-coated discs also included osteopontin that was covalently attached to the tetraglyme coating.

Tetraglyme coatings were prepared by subjecting the disks to Radio Frequency Plasma Discharge deposition of vapor phase tetra (ethylene) glycol 10 dimethyl ether (tetra GLYME) as described in U.S. Patents 5,153,072, and 5,002,794, (both of which patents are incorporated herein by reference). The GLYME-coated disks were sterilized with 70% ethanol/water, and filter-sterilized solutions of osteopontin were covalently immobilized to the tetraglyme coating by using disuccimidyl carbonate to activate carboxyls and hydroxyls on the glyme 15 surface, either by reacting an allylamine glyme film with succinic anhydride, or by using the native reactive groups of the glyme film.

Method of implanting polyethylene disks : Materials were implanted in at least quadruplicate (into 4 different mice) for four weeks. Strict aseptic technique 20 were used. All materials were sterilized by an overnight soak in sterile 70% ethanol, followed by three 20-minute washes in sterile, pyrogen free water. All instruments were autoclaved prior to surgery, and soaked in 70% ethanol between animals.

The materials were surgically implanted beneath the skin on the backs (dorsal side) of male mice using aseptic technique. Animals were anesthetized with a cocktail of ketamine and xylazine. The incision site was prepared by shaving, 25 swabbing with Betadine followed by a 70% alcohol wipe. A single 1-1.5 cm incision was made midline on the back of each mouse, and two subcutaneous pockets were created by blunt dissection lateral to each side of the incision. One implant was placed in each pocket, and the incision was closed with sterile wound clips. Occasionally a second incision was made to accommodate two more implants, using 30 the exact procedure as described above. Animals were allowed to recover prior to

returning to housing cages. Animals were given food and water *ad libidum* for the remainder of the four week study.

After four weeks, animals were sacrificed by CO<sub>2</sub> asphyxiation, wound clips were removed, and implants were retrieved *en-bloc* in an effort to not disturb the biomaterial/host tissue interface. Explants were fixed with methyl Carnoy's or embedded and frozen immediately in liquid nitrogen. Chemically fixed explants were processed, embedded in paraffin and sectioned. Several sections of each explant were stained with haematoxylin and eosin (H&E) or Masson's trichrome. The remaining sections were kept in reserve for immunocytochemical staining.

10        Quantification of foreign body capsule thickness: Tissue samples were taken from wild-type mice at four weeks after implantation of polyethylene disks which were either uncoated, coated with a non-fouling (RFGD tetraglyme) coating, or coated with a non-fouling (RFGD tetraglyme) coating that included OPN covalently immobilized to the glyme coating. The thickness of the foreign body capsule surrounding the implants was measured. Capsule thickness was measured by light microscopy using an ocular reticule that had been previously calibrated using a stage micrometer. 5 equi-distant points along the length of a single section were chosen for measurement, and capsule thickness was measured at the tissue/material interface on both surfaces of the implant (skin side and fat or muscle side) at each of 15 these 5 points. Thus, 10 measurements were made for each implant.

As shown in FIGURE 8A, the uncoated disk resulted in the thickest capsule, the glyme coating reduced the thickness of the foreign body capsule, and the glyme coating including the immobilized OPN was associated with a marked reduction in fibrous capsule thickness.

25        Quantification of macrophage infiltration: The tissue samples as described above were also analyzed with respect to macrophage infiltration of the foreign body capsule. As shown in FIGURE 8B, the results correlated with the capsule thickness; the uncoated disks had the highest level of macrophage infiltration, followed by the glyme coating, and the lowest macrophage score was found in the glyme coating 30 containing the immobilized OPN.

These results demonstrate that OPN immobilized on the surface of a device implanted into an animal body reduces the foreign body reaction to the implant.

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without  
5 departing from the spirit and scope of the invention.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of modulating the amount or biological activity of thrombospondin 2 or osteopontin in an animal, said method comprising the step of introducing into the animal an amount of a molecule, selected from the group consisting of osteopontin and a thrombospondin 2 antagonist, effective to modulate the amount or biological activity of thrombospondin 2 or osteopontin in the animal.
2. The method of Claim 1 wherein an antagonist of thrombospondin 2 is introduced into the animal.
3. The method of Claim 2 wherein the amount or biological activity of thrombospondin 2 is decreased by said antagonist of thrombospondin 2.
4. The method of Claim 2 wherein the thrombospondin 2 antagonist is selected from the group consisting of an antisense thrombospondin 2 nucleic acid molecule, an anti-thrombospondin 2 antibody, a thrombospondin 2 blocking peptide and a thrombospondin 2 ribozyme.
5. The method of Claim 4 wherein an antisense thrombospondin 2 nucleic acid molecule is introduced into the animal.
6. The method of Claim 5 wherein the antisense thrombospondin 2 nucleic acid molecule is at least ninety percent identical to the complement of a thrombospondin 2 cDNA consisting of the nucleic acid sequence set forth in SEQ ID NO. 3.
7. The method of Claim 5 wherein the antisense thrombospondin 2 nucleic acid molecule hybridizes under stringent conditions to a thrombospondin 2 cDNA molecule consisting of the nucleic acid sequence set forth in SEQ ID NO. 3.
8. The method of Claim 4 wherein an anti-thrombospondin 2 antibody is introduced into the animal.

9. The method of Claim 4 wherein a thrombospondin 2 blocking peptide is introduced into the animal.

10. The method of Claim 4 wherein a thrombospondin 2 ribozyme is introduced into the animal.

11. The method of Claim 1 wherein osteopontin is introduced into the animal.

12. The method of Claim 1 wherein the molecule is introduced into the animal by a method selected from the group consisting of injection, as a component of a lipid complex, as a component of an implanted porous matrix, and by immobilization onto an implanted surface.

13. The method of Claim 5 wherein an antisense thrombospondin 2 nucleic acid molecule is incorporated within a delivery device which is introduced into the animal.

14. The method of Claim 13 wherein the delivery device comprises a porous matrix wherein the thrombospondin 2 antisense nucleic acid molecule is disposed.

15. The method of Claim 1 wherein the animal is exhibiting a wound response, and the amount of the introduced molecule is effective to [reduce] improve the wound response.

16. The method of Claim 15 wherein the molecule is an antisense thrombospondin 2 nucleic acid molecule.

17. The method of Claim 1 wherein osteopontin and an antagonist of thrombospondin 2 are introduced into the animal.


18. The method of Claim 17 wherein the antagonist to thrombospondin 2 is an antisense thrombospondin 2 nucleic acid molecule.

19. A medical device comprising:
  - (a) a device body; and
  - (b) a surface layer attached to the device body, said surface layer comprising an amount of an agonist or antagonist of a matricellular protein sufficient to reduce the foreign body response against the device, wherein said device is adapted to be affixed to, or implanted within, the soft tissue of an animal.
20. The medical device of Claim 19 wherein the device is selected from the group of devices consisting of wholly implanted medical devices, partially implanted medical devices, and surface medical devices.
21. The medical device of Claim 19 wherein the surface layer attached to the device body comprises a porous matrix.
22. The medical device of Claim 19 further comprising a multiplicity of surface of layers disposed one upon the other, wherein at least one of said surface layers comprises an agonist or antagonist of a matricellular protein.
23. The medical device of Claim 22 wherein the device comprises: (a) a first surface layer comprising a first agonist, or first antagonist, of a matricellular protein; and (b) a second surface layer comprising a second agonist, or second antagonist, of a matricellular protein, wherein said first agonist is different from said second agonist and said first antagonist is different from said second antagonist.
24. The medical device of Claim 22 wherein the device comprises: (a) a first surface layer comprising osteopontin; and (b) a second surface layer comprising a thrombospondin 2 antagonist, wherein said first surface layer is disposed external to said second surface layer.
25. The medical device of Claim 24 wherein said thrombospondin 2 antagonist is an antisense nucleic acid molecule.


26. The medical device of Claim 19 wherein the surface layer comprises:  
(a) a first area comprising a first agonist or first antagonist of a matricellular protein;  
and (b) a second area comprising a second agonist or second antagonist, wherein the first agonist is different from the second agonist and the first antagonist is different from the second antagonist.

27. The method of Claim 1 wherein the animal is exhibiting a foreign body response, and the amount of the introduced molecule is effective to reduce the foreign body response.

1/4






*Fig. 1.*





*Fig. 2.*


2/4




3/4

*Fig. 6.**Fig. 7.*

4/4



*Fig. 8A.*



*Fig. 8B.*

## SEQUENCE LISTING

&lt;110&gt; University of Washington

&lt;120&gt; Methods and Devices to Modulate the Wound Response

&lt;130&gt; UO FW117807

&lt;150&gt; US 60/222,071

&lt;151&gt; 2000-08-01

&lt;160&gt; 4

&lt;170&gt; PatentIn version 3.0

&lt;210&gt; 1

&lt;211&gt; 1469

&lt;212&gt; DNA

&lt;213&gt; Homo Sapien

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (102)..(1001)

&lt;400&gt; 1

agcagcagga ggaggcagag cacagcatcg tcgggaccag actcgctca ggccagttgc 60

agccttctca gccaaacgcc gaccaaggaa aactcactac c atg aga att gca gtg 116  
Met Arg Ile Ala Val  
1 5att tgc ttt tgc ctc cta ggc atc acc tgt gcc ata cca gtt aaa cag 164  
Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala Ile Pro Val Lys Gln  
10 15 20gct gat tct gga agt tct gag gaa aag cag ctt tac aac aaa tac cca 212  
Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu Tyr Asn Lys Tyr Pro  
25 30 35gat gct gtg gcc aca tgg cta aac cct gac cca tct cag aag cag aat 260  
Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro Ser Gln Gln Asn  
40 45 50ctc cta gcc cca cag acc ctt cca agt aag tcc aac gaa agc cat gac 308  
Leu Leu Ala Pro Gln Thr Leu Pro Ser Lys Ser Asn Glu Ser His Asp  
55 60 65cac atg gat gat atg gat gaa gat gat gat gac cat gtg gac agc 356  
His Met Asp Asp Met Asp Asp Glu Asp Asp Asp His Val Asp Ser  
70 75 80 85cag gac tcc att gac tcg aac gac tct gat gat gta gat gac act gat 404  
Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp Val Asp Asp Thr Asp  
90 95 100gat tct cac cag tct gat gag tct cac cat tct gat gaa tct gat gaa 452  
Asp Ser His Gln Ser Asp Glu Ser His His Ser Asp Glu Ser Asp Glu  
105 110 115ctg gtc act gat ttt ccc acg gac ctg cca gca acc gaa gtt ttc act 500  
Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu Val Phe Thr  
120 125 130cca gtt gtc ccc aca gta gac aca tat g<sub>1</sub>t ggc cga ggt gat agt gtg 548

Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val			
135	140	145	
gtt tat gga ctg agg tca aaa tct aag aag ttt cgc aga cct gac atc		596	
Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg Pro Asp Ile			
150	155	160	165
cag tac cct gat gct aca gac gag gac atc acc tca cac atg gaa agc		644	
Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr Ser His Met Glu Ser			
170	175	180	
gag gag ttg aat ggt gca tac aag gcc atc ccc gtt gcc cag gac ctg		692	
Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro Val Ala Gln Asp Leu			
185	190	195	
aac gcg cct tct gat tgg gac agc cgt ggg aag gac agt tat gaa acg		740	
Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser Tyr Glu Thr			
200	205	210	
agt cag ctg gat gac cag agt gct gaa acc cac agc cac aag cag tcc		788	
Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His Ser His Lys Gln Ser			
215	220	225	
aga tta tat aag cgg aaa gcc aat gat gag agc aat gag cat tcc gat		836	
Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Asn Glu His Ser Asp			
230	235	240	245
gtg att gat agt cag gaa ctt tcc aaa gtc agc cgt gaa ttc cac agc		884	
Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg Glu Phe His Ser			
250	255	260	
cat gaa ttt cac agc cat gaa gat atg ctg gtt gta gac ccc aaa agt		932	
His Glu Phe His Ser His Glu Asp Met Leu Val Val Asp Pro Lys Ser			
265	270	275	
aag gaa gaa gat aaa cac ctg aaa ttt cgt att tct cat gaa tta gat		980	
Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser His Glu Leu Asp			
280	285	290	
agt gca tct tct gag gtc aat taaaaggaga aaaaatacaa tttctcactt		1031	
Ser Ala Ser Ser Glu Val Asn			
295	300		
tgcatttagt caaaagaaaa aatgcatttat agcaaatga aagagaacat gaaatgcttc		1091	
tttctcagtt tattgggtga atgtgtatct atttgagtct ggaaataact aatgtgtttg		1151	
ataattagtt tagtttgtgg cttcatggaa actccctgta aactaaaagc ttcagggtta		1211	
tgtctatgtt cattctatag aagaaatgca aactatcaact gtattttaat atttgttatt		1271	
ctctcatgaa tagaaattta tgtagaagca aacaaaatac ttttaccac ttaaaaagag		1331	
aatataacat tttatgtcac tataatcttt tgtttttaa gtttgttat atttgttgt		1391	
gattatcttt ttgtgggtgtg aataaatctt ttatcttcaa tgtaataaga aaaaaaaaaa		1451	
aaaaacaaaaa aaaaaaaaaa		1469	

<210> 2  
<211> 300  
<212> PRT  
<213> Homo Sapien

&lt;400&gt; 2

Met Arg Ile Ala Val Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala  
1 5 10 15

Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu  
20 25 30

Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro  
35 40 45

Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Thr Leu Pro Ser Lys Ser  
50 55 60

Asn Glu Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp  
65 70 75 80

Asp His Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp  
85 90 95

Val Asp Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser  
100 105 110

Asp Glu Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala  
115 120 125

Thr Glu Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly  
130 135 140

Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe  
145 150 155 160

Arg Arg Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr  
165 170 175

Ser His Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro  
180 185 190

Val Ala Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys  
195 200 205

Asp Ser Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His  
210 215 220

Ser His Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser  
225 230 235 240

Asn Glu His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser

245

250

255

Val Asp Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile  
275 280 285

Ser	His	Glu	Leu	Asp	Ser	Ala	Ser	Ser	Glu	Val	Asn
290					295						300

<210> 3  
<211> 5784  
<212> DNA  
<213> Homo Sapien

<220>  
<221> CDS  
<222> (240) .. (3755)

<400> 3

acgggcatcca gtacagaggg gctggacttg gaccctcgca gcagccctgc acaggagaag 60

cggtatataa agcccgccctg cccggggagcc gctccggccac gtccacccgga gcattccctgca 120

caa gct ggt cac cag gac aaa gac acg acc ttc gac ctt ttc agt atc 335  
 Gln Ala Gly His Gln Asp Lys Asp Thr Thr Phe Asp Leu Phe Ser Ile  
 20 25 30

agc aac atc aac cgc aag acc att ggc gcc aag cag ttc cgc ggg ccc 383  
Ser Asn Ile Asn Arg Lys Thr Ile Gly Ala Lys Gln Phe Arg Gly Pro.  
35 40 45

gac ccc ggc gtg ccg gct tac cgc ttc gtg cgc ttt gac tac atc cca 431  
Asp Pro Gly Val Pro Ala Tyr Arg Phe Val Arg Phe Asp Tyr Ile Pro  
50 55 60

ccg gtg aac gca gat gac ctc agc aag atc acc aag atc atg cg<sup>479</sup>  
 Pro Val Asn Ala Asp Asp Leu Ser Lys Ile Thr Lys Ile Met Arg Gln  
 65 70 75 80

aag gag ggc ttc ttc ctc acg gcc cag ctc aag cag gac ggc aag tcc 527  
Lys Glu Gly Phe Phe Leu Thr Ala Gln Ieu Lys Gln Asp Gly Lys Ser  
85 89 95

agg ggc acg ctg ttg gct ctg gag ggc ccc ggt ctc tcc cag agg cag 575  
Arg Gly Thr Leu Leu Ala Leu Glu Gly Pro Gly Leu Ser Gln Arg Gln  
100 105 110

ttc gag atc gtc 'tcc aac ggc ccc gcg gac acg ctg gat ctc acc tac 623  
Phe Glu Ile Val Ser Asn Gly Pro Ala Asp Thr Leu Asp Leu Thr Tyr  
115 120 125

tgg att gac ggc acc cgg cat gtg gtc tcc ctg gag gac gtc ggc ctg Trp Ile Asp Gly Thr Arg His Val Val Ser Leu Glu Asp Val Gly Leu 130 135 140	671
gct gac tcg cag tgg aag aac gtc acc gtg cag gtg gct ggc gag acc Ala Asp Ser Gln Trp Lys Asn Val Thr Val Gln Val Ala Gly Glu Thr 145 150 155 160	719
tac agc ttg cac gtg ggc tgc gac ctc ata gga cca gtt gct ctg gac Tyr Ser Leu His Val Gly Cys Asp Leu Ile Gly Pro Val Ala Leu Asp 165 170 175	767
gag ccc ttc tac gag cac ctg cag gcg gaa aag agc cgg atg tac gtg Glu Pro Phe Tyr Glu His Leu Gln Ala Glu Lys Ser Arg Met Tyr Val 180 185 190	815
gcc aaa ggc tct gcc aga gag agt cac ttc agg ggt ttg ctt cag aac Ala Lys Gly Ser Ala Arg Glu Ser His Phe Arg Gly Leu Leu Gln Asn 195 200 205	863
gtc cac cta gtg ttt gaa aac tct gtg gaa gat att cta agc aag aag Val His Leu Val Phe Glu Asn Ser Val Glu Asp Ile Leu Ser Lys Lys 210 215 220	911
ggc tgc cag caa ggc cag gga gct gag atc aac gcc atc agt gag aac Gly Cys Gln Gln Gly Gln Ala Glu Ile Asn Ala Ile Ser Glu Asn 225 230 235 240	959
aca gag acg ctg cgc ctg ggt ccg cat gtc acc acc gag tac gtg ggc Thr Glu Thr Leu Arg Leu Gly Pro His Val Thr Thr Glu Tyr Val Gly 245 250 255	1007
ccc agc tcg gag agg agg ccc gag gtg tgc gaa cgc tcg tgc gag gag Pro Ser Ser Glu Arg Arg Pro Glu Val Cys Glu Arg Ser Cys Glu Glu 260 265 270	1055
ctg gga aac atg gtc cag gag ctc tcg ggg ctc cac gtc ctc gtg aac Leu Gly Asn Met Val Gln Glu Leu Ser Gly Leu His Val Leu Val Asn 275 280 285	1103
cag ctc agc gag aac ctc aag aga gtg tcg aat gat aac cag ttt ctc Gln Leu Ser Glu Asn Leu Lys Arg Val Ser Asn Asp Asn Gln Phe Leu 290 295 300	1151
tgg gag ctc att ggt ggc cct aag aca agg aac atg tca gct tgc Trp Glu Leu Ile Gly Gly Pro Pro Lys Thr Arg Asn Met Ser Ala Cys 305 310 315 320	1199
tgg cag gat ggc cgg ttc ttt gcg gaa aat gaa acg tgg gtg gtg gac Trp Gln Asp Gly Arg Phe Phe Ala Glu Asn Glu Thr Trp Val Val Asp 325 330 335	1247
agc tgc acc acg tgt acc tgc aag aaa ttt aaa acc att tgc cac caa Ser Cys Thr Thr Cys Thr Cys Lys Lys Phe Lys Thr Ile Cys His Gln 340 345 350	1295
atc acc tgc ccc cct gca acc tgc gcc agt cca tcc ttt gtg gaa ggc Ile Thr Cys Pro Pro Ala Thr Cys Ala Ser Pro Ser Phe Val Glu Gly 355 360 365	1343
gaa tgc tgc cct tcc tgc ctc cac tcg gtg gac ggt gag gag ggc tgg Glu Cys Cys Pro Ser Cys Leu His Ser Val Asp Gly Glu Glu Gly Trp 370 375 380	1391

tct ccg tgg gca gag tgg acc cag tgc tcc gtg acg tgt ggc tct ggg Ser Pro Trp Ala Glu Trp Thr Gln Cys Ser Val Thr Cys Gly Ser Gly 385                   390                   395                   400	1439
acc cag cag aga ggc cggtcc tgt gac gtc acc aac acc tgc ttg Thr Gln Gln Arg Gly Arg Ser Cys Asp Val Thr Ser Asn Thr Cys Leu 405                   410                   415	1487
ggg ccc tcg atc cag aca cgg gct tgc agt ctg agc aag tgt gac acc Gly Pro Ser Ile Gln Thr Arg Ala Cys Ser Leu Ser Lys Cys Asp Thr 420                   425                   430	1535
cgc atc cgg cag gac ggc ggc tgg agc cac tgg tca cct tgg tct tca Arg Ile Arg Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser 435                   440                   445	1583
tgc tct gtg acc tgt gga gtt ggc aat atc aca cgc atc cgt ctc tgc Cys Ser Val Thr Cys Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys 450                   455                   460	1631
aac tcc cca gtg ccc cag atg ggg ggc aag aat tgc aaa ggg agt ggc Asn Ser Pro Val Pro Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly 465                   470                   475                   480	1679
cgg gag acc aaa gcc tgc cag ggc gcc cca tgc cca atc gat ggc cgc Arg Glu Thr Lys Ala Cys Gln Gly Ala Pro Cys Pro Ile Asp Gly Arg 485                   490                   495	1727
tgg agc ccc tgg tcc ccg tgg tgc act gtc acc tgt gcc ggt Trp Ser Pro Trp Ser Pro Trp Ser Ala Cys Thr Val Thr Cys Ala Gly 500                   505                   510	1775
ggg atc cgg gag cgc acc cgg gtc tgc aac agc cct gag cct cag tac Gly Ile Arg Glu Arg Thr Arg Val Cys Asn Ser Pro Glu Pro Gln Tyr 515                   520                   525	1823
gga ggg aag gcc tgc gtg ggg gat gtg cag gag cgt cag atg tgc aac Gly Gly Lys Ala Cys Val Gly Asp Val Gln Glu Arg Gln Met Cys Asn 530                   535                   540	1871
aag agg agc tgc ccc gtg gat ggc tgt tta tcc aac ccc tgc ttc ccg Lys Arg Ser Cys Pro Val Asp Gly Cys Leu Ser Asn Pro Cys Phe Pro 545                   550                   555                   560	1919
gga gcc cag tgc agc agc ttc ccc gat ggg tcc tgg tca tgc ggc ttc Gly Ala Gln Cys Ser Ser Phe Pro Asp Gly Ser Trp Ser Cys Gly Phe 565                   570                   575	1967
tgc cct gtg ggc ttc ttg ggc aat ggc acc cac tgt gag gac ctg gac Cys Pro Val Gly Phe Leu Gly Asn Gly Thr His Cys Glu Asp Leu Asp 580                   585                   590	2015
gag tgt gcc ctg gtc ccc gac atc tgc ttc tcc acc agc aag gtg cct Glu Cys Ala Leu Val Pro Asp Ile Cys Phe Ser Thr Ser Lys Val Pro 595                   600                   605	2063
cgc tgt gtc aac act cag cct ggc ttc cac tgc ctg ccc tgc ccg ccc Arg Cys Val Asn Thr Gln Pro Gly Phe His Cys Leu Pro Cys Pro Pro 610                   615                   620	2111
cga tac aga ggg aac cag ccc gtc ggg gtc ggc ctg gaa gca gcc aag Arg Tyr Arg Gly Asn Gln Pro Val Gly Val Gly Leu Glu Ala Ala Lys 625                   630                   635                   640	2159

acg gaa aag caa gtg tgt gag ccc gaa aac cca tgc aag gac aag aca Thr Glu Lys Gln Val Cys Glu Pro Glu Asn Pro Cys Lys Asp Lys Thr 645 650 655	2207
cac aac tgc cac aag cac gcg gag tgc atc tac ctg ggt cac ttc agc His Asn Cys His Lys His Ala Glu Cys Ile Tyr Leu Gly His Phe Ser 660 665 670	2255
gac ccc atg tac aag tgc gag tgc cag aca ggc tac gcg ggc gac ggg Asp Pro Met Tyr Lys Cys Glu Cys Gln Thr Gly Tyr Ala Gly Asp Gly 675 680 685	2303
ctc atc tgc ggg gag gac tcg gac ctg gac ggc tgg ccc aac ctc aat Leu Ile Cys Gly Glu Asp Ser Asp Leu Asp Gly Trp Pro Asn Leu Asn 690 695 700	2351
ctg gtc tgc gcc acc aac gcc acc tac cac tgc atc aag gat aac tgc Leu Val Cys Ala Thr Asn Ala Thr Tyr His Cys Ile Lys Asp Asn Cys 705 710 715 720	2399
ccc cat ctg cca aat tct ggg cag gaa gac ttt gac aag gac ggg att Pro His Leu Pro Asn Ser Gly Gln Glu Asp Phe Asp Lys Asp Gly Ile 725 730 735	2447
ggc gat gcc tgt gat gat gac gat aat gac ggt gtg acc gat gag Gly Asp Ala Cys Asp Asp Asp Asp Asn Asp Gly Val Thr Asp Glu 740 745 750	2495
aag gac aac tgc cag ctc ctc ttc aat ccc cgc cag gct gac tat gac Lys Asp Asn Cys Gln Leu Leu Phe Asn Pro Arg Gln Ala Asp Tyr Asp 755 760 765	2543
aag gat gag gtt ggg gac cgc tgt gac aac tgc cct tac gtg cac aac Lys Asp Glu Val Gly Asp Arg Cys Asp Asn Cys Pro Tyr Val His Asn 770 775 780	2591
cct gcc cag atc gac aca gac aac aat gga gag ggt gac gcc tgc tcc Pro Ala Gln Ile Asp Thr Asp Asn Asn Gly Glu Gly Asp Ala Cys Ser 785 790 795 800	2639
gtg gac att gat ggg gac gat gtc ttc aat gaa cga gac aat tgt ccc Val Asp Ile Asp Gly Asp Asp Val Phe Asn Glu Arg Asp Asn Cys Pro 805 810 815	2687
tac gtc tac aac act gac cag agg gac acg gat ggt gac ggt gtg ggg Tyr Val Tyr Asn Thr Asp Gln Arg Asp Thr Asp Gly Asp Gly Val Gly 820 825 830	2735
gat cac tgt gac aac tgc ccc ctg gtg cac aac cct gac cag acc gac Asp His Cys Asp Asn Cys Pro Ile Val His Asn Pro Asp Gln Thr Asp 835 840 845	2783
gtg gac aat gac ctt gtt ggg gac cag tgt gac aac aac gag gac ata Val Asp Asn Asp Leu Val Gly Asp Gln Cys Asp Asn Asn Glu Asp Ile 850 855 860	2831
gat gac gac ggc cac cag aac aac cag gac aac tgc ccc tac atc tcc Asp Asp Asp Gly His Gln Asn Asn Gln Asp Asn Cys Pro Tyr Ile Ser 865 870 875 880	2879
aac gcc aac cag gct gac cat gac aga gac ggc cag ggc gac gcc tgt Asn Ala Asn Gln Ala Asp His Asp Arg Asp Gly Gln Gly Asp Ala Cys 885 890 895	2927

gac cct gat gat gac aac gat ggc gtc ccc gat gac agg gac aac tgc Asp Pro Asp Asp Asn Asp Gly Val Pro Asp Asp Arg Asp Asn Cys 900 905 910	2975
cgg ctt gtg ttc aac cca gac cag gag gac ttg gac ggt gat gga cgg Arg Leu Val Phe Asn Pro Asp Gln Glu Asp Leu Asp Gly Asp Gly Arg 915 920 925	3023
ggt gat att tgt aaa gat gat ttt gac aat gac aac atc cca gat att Gly Asp Ile Cys Lys Asp Asp Phe Asp Asn Asp Asn Ile Pro Asp Ile 930 935 940	3071
gat gat gtg tgt cct gaa aac aat gcc atc agt gag aca gac ttc agg Asp Asp Val Cys Pro Glu Asn Asn Ala Ile Ser Glu Thr Asp Phe Arg 945 950 955 960	3119
aac ttc cag atg gtc ccc ttg gat ccc aaa ggg acc acc caa att gat Asn Phe Gln Met Val Pro Leu Asp Pro Lys Gly Thr Thr Gln Ile Asp 965 970 975	3167
ccc aac tgg gtc att cgc cat caa ggc aag gag ctg gtt cag aca gcc Pro Asn Trp Val Ile Arg His Gln Gly Lys Glu Leu Val Gln Thr Ala 980 985 990	3215
aac tcg gac ccc ggc atc gct gta ggt ttt gac gag ttt ggg tct gtg Asn Ser Asp Pro Gly Ile Ala Val Gly Phe Asp Glu Phe Gly Ser Val 995 1000 1005	3263
gac ttc agt ggc aca ttc tac gta aac act gac cgg gac gac gac Asp Phe Ser Gly Thr Phe Tyr Val Asn Thr Asp Arg Asp Asp Asp 1010 1015 1020	3308
tat gct ggc ttc gtc ttt ggt tac cag tca agc agc cgc ttc tat Tyr Ala Gly Phe Val Phe Gly Tyr Gln Ser Ser Ser Arg Phe Tyr 1025 1030 1035	3353
gtg gtg atg tgg aag cag gtg acg cag acc tac tgg gag gac cag Val Val Met Trp Lys Gln Val Thr Gln Thr Tyr Trp Glu Asp Gln 1040 1045 1050	3398
ccc acg cgg gcc tat ggc tac tcc ggc gtg tcc ctc aag gtg gtg Pro Thr Arg Ala Tyr Gly Tyr Ser Gly Val Ser Leu Lys Val Val 1055 1060 1065	3443
aac tcc acc acg ggg acg ggc gag cac ctg agg aac gcg ctg tgg Asn Ser Thr Thr Gly Thr Gly Glu His Leu Arg Asn Ala Leu Trp 1070 1075 1080	3488
cac acg ggg aac acg ccg ggg cag gtg cga acc tta tgg cac gac His Thr Gly Asn Thr Pro Gly Gln Val Arg Thr Leu Trp His Asp 1085 1090 1095	3533
ccc agg aac att ggc tgg aag gac tac acg gcc tat agg tgg cac Pro Arg Asn Ile Gly Trp Lys Asp Tyr Thr Ala Tyr Arg Trp His 1100 1105 1110	3578
ctg act cac agg ccc aag acc ggc tac atc aga gtc tta gtg cat Leu Thr His Arg Pro Lys Thr Gly Tyr Ile Arg Val Leu Val His 1115 1120 1125	3623
gaa gga aaa cag gtc atg gca gac tca gga cct atc tat gac caa Glu Gly Lys Gln Val Met Ala Asp Ser Gly Pro Ile Tyr Asp Gln 1130 1135 1140	3668

acc tac gct ggc ggg cgg ctg ggt cta ttt gtc ttc tct caa gaa	3713
Thr Tyr Ala Gly Gly Arg Leu Gly Leu Phe Val Phe Ser Gln Glu	
1145 1150 1155	
atg gtc tat ttc tca gac ctc aag tac gaa tgc aga gat att	3755
Met Val Tyr Phe Ser Asp Leu Lys Tyr Glu Cys Arg Asp Ile	
1160 1165 1170	
taaaacaagat ttgctgcatt tccggcaatg ccctgtgcat gccatggtcc ctagacacct	3815
cagttcattg tggccttgc ggcttctctc tctagcagca cctcctgtcc cttgacctta	3875
actctgtatgg ttcttcaccc cctgccagca accccaaacc caagtgcctt cagaggataa	3935
atatcaatgg aactcagaga tgaacatcta acccactaga ggaaaccagt ttggtgat	3995
atgagacttt atgtggagtg aaaattgggc atgccattac attgctttt cttgtttgtt	4055
taaaaagaat gacgtttaca tataaaatgt aattacttat tgtatttatg tgtatatgga	4115
gttgaaggga atactgtgca taagccatta tgataaatta agcatgaaaa atattgctga	4175
actactttt gtgcttaaag ttgtcaactat tcttgaatta gagttgctct acaatgacac	4235
acaaatcccg ctaaataaat tataaacaag ggtcaattca aatttgaagt aatgttttag	4295
taaggagaga ttagaagaca acaggcatag caaatgacat aagctaccga ttaactaattc	4355
ggaacatgta aaacagttac aaaaataaac gaactctcct cttgtcctac aatgaaagcc	4415
ctcatgtgca gtagagatgc agtttcatca aagaacaaac atccttgcaa atgggtgtga	4475
cgcggttcca gatgtggatt tggcaaaacc tcatttaagt aaaaggttag cagagcaaag	4535
tgcggtgctt tagctgctgc ttgtccgtt gtggcgtcgg ggaggctctt gcctgagctt	4595
ccttccccag ctttgcgtcc tgagaggaac cagagcagac gcacaggccg gaaaaggcgc	4655
atctaacgcg tatctaggct ttggtaactg cggacaagtt gctttaccc gatttgatga	4715
tacatttcat taaggttcca gttataaata ttttgttaat atttattaag tgactataga	4775
atgcaactcc atttaccagt aacttatttt aaatatgcct agtaacacat atgttagtata	4835
atttctagaa acaaacatct aataagtata taatcctgtg aaaatatgag gcttgataat	4895
attaggttgt cacgatgaag catgctagaa gctgtaacag aatacataga gaataatgag	4955
gagtttatga tggAACCTTA atatataatg ttGCCAGCGA ttttagttca atatttgtt	5015
ctgttatcta tctgctgtat atgaaattct ttAAATTCAA acgctgaaaa cgaatcagca	5075
tttagtcttgc ccaataatca gtcattgtgt atatgcacaa gtttgtttt	5135
gtttttgttt tttttgttgg ttggTTTTTG TGCTTAAAGT TGCATGATCT TTCTGCAGGA	5195
aatagtcaact catcccactc cacataaggg gtttagtaag agaagtctgt ctgtctgtat	5255
atggataggg ggcaaattttt tttcccccttt ctgttaatag tcattcacatt tctatgccaa	5315
acaggaacga tccataactt tagtcttaat gtacacattt cattttgata aaattaattt	5375
tgttgtttcc tttgaggtttgc atcgTTGTGT TGTtttGCTG CACTTTTAC TTTTTGCGT	5435

gtggagctgt attcccgaga caacgaagcg ttgggatact tcattaaatg tagcgactgt 5495  
 caacagcgtg caggtttct gtttctgtgt tgtgggtca accgtacaat ggtgtggaa 5555  
 tgacgatgtat gtgaatatattt agaatgtacc atattttttg taaattattt atgttttct 5615  
 aaacaaattt atcgtatagg ttgatgaaac gtcatgtgtt ttgccaaaga ctgtaaatat 5675  
 ttatttatgt gtcacatgg tcaaaatttc accactgaaa ccctgcactt agctagaacc 5735  
 tcattttaa agattaacaa caggaataa attgtaaaaa aggtttct 5784

<210> 4  
<211> 1172  
<212> PRT  
<213> Homo Sapien

<400> 4

Met Val Trp Arg Leu Val Leu Leu Ala Leu Trp Val Trp Pro Ser Thr  
 1 5 10 15

Gln Ala Gly His Gln Asp Lys Asp Thr Thr Phe Asp Leu Phe Ser Ile  
 20 25 30

Ser Asn Ile Asn Arg Lys Thr Ile Gly Ala Lys Gln Phe Arg Gly Pro  
 35 40 45

Asp Pro Gly Val Pro Ala Tyr Arg Phe Val Arg Phe Asp Tyr Ile Pro  
 50 55 60

Pro Val Asn Ala Asp Asp Leu Ser Lys Ile Thr Lys Ile Met Arg Gln  
 65 70 75 80

Lys Glu Gly Phe Phe Leu Thr Ala Gln Leu Lys Gln Asp Gly Lys Ser  
 85 90 95

Arg Gly Thr Leu Leu Ala Leu Glu Gly Pro Gly Leu Ser Gln Arg Gln  
 100 105 110

Phe Glu Ile Val Ser Asn Gly Pro Ala Asp Thr Leu Asp Leu Thr Tyr  
 115 120 125

Trp Ile Asp Gly Thr Arg His Val Val Ser Leu Glu Asp Val Gly Leu  
 130 135 140

Ala Asp Ser Gln Trp Lys Asn Val Thr Val Gln Val Ala Gly Glu Thr  
 145 150 155 160

Tyr Ser Leu His Val Gly Cys Asp Leu Ile Gly Pro Val Ala Leu Asp  
 165 170 175

Glu Pro Phe Tyr Glu His Leu Gln Ala Glu Lys Ser Arg Met Tyr Val  
           180                 185                 190

Ala Lys Gly Ser Ala Arg Glu Ser His Phe Arg Gly Leu Leu Gln Asn  
195 200 205

Val His Leu Val Phe Glu Asn Ser Val Glu Asp Ile Leu Ser Lys Lys  
210 215 220

Gly Cys Gln Gln Gly Gln Gly Ala Glu Ile Asn Ala Ile Ser Glu Asn  
225 230 235 240

Thr Glu Thr Leu Arg Leu Gly Pro His Val Thr Thr Glu Tyr Val Gly  
245 250 255

Pro Ser Ser Glu Arg Arg Pro Glu Val Cys Glu Arg Ser Cys Glu Glu  
260 265 270

Leu Gly Asn Met Val Gln Glu Leu Ser Gly Leu His Val Leu Val Asn  
 275 280 285

Gln Leu Ser Glu Asn Leu Lys Arg Val Ser Asn Asp Asn Gln Phe Leu  
290 295 300

Trp Glu Leu Ile Gly Gly Pro Pro Lys Thr Arg Asn Met Ser Ala Cys  
 305                   310                   315                   320

Trp Gln Asp Gly Arg Phe Phe Ala Glu Asn Glu Thr Trp Val Val Asp  
           325                         330                         335

Ser Cys Thr Thr Cys Thr Cys Lys Lys Phe Lys Thr Ile Cys His Gln  
           340                   345                   350

Ile Thr Cys Pro Pro Ala Thr Cys Ala Ser Pro Ser Phe Val Glu Gly  
355 360 365

Glu Cys Cys Pro Ser Cys Leu His Ser Val Asp Gly Glu Glu Gly Trp  
 370 375 380

Ser Pro Trp Ala Glu Trp Thr Gln Cys Ser Val Thr Cys Gly Ser Gly  
 385                   390                   395                   400

Thr Gln Gln Arg Gly Arg Ser Cys Asp Val Thr Ser Asn Thr Cys Leu  
 405 410 415

Gly Pro Ser Ile Gln Thr Arg Ala Cys Ser Leu Ser Lys Cys Asp Thr  
 420 425 430

Arg Ile Arg Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser  
435 440 445

Cys Ser Val Thr Cys Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys  
450 455 460

Asn Ser Pro Val Pro Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly  
465 470 475 480

Arg Glu Thr Lys Ala Cys Gln Gly Ala Pro Cys Pro Ile Asp Gly Arg  
485 490 495

Trp Ser Pro Trp Ser Pro Trp Ser Ala Cys Thr Val Thr Cys Ala Gly  
500 505 510

Gly Ile Arg Glu Arg Thr Arg Val Cys Asn Ser Pro Glu Pro Gln Tyr  
515 520 525

Gly Gly Lys Ala Cys Val Gly Asp Val Gln Glu Arg Gln Met Cys Asn  
530 535 540

Lys Arg Ser Cys Pro Val Asp Gly Cys Leu Ser Asn Pro Cys Phe Pro  
545 550 555 560

Gly Ala Gln Cys Ser Ser Phe Pro Asp Gly Ser Trp Ser Cys Gly Phe  
565 570 575

Cys Pro Val Gly Phe Leu Gly Asn Gly Thr His Cys Glu Asp Leu Asp  
580 585 590

Glu Cys Ala Leu Val Pro Asp Ile Cys Phe Ser Thr Ser Lys Val Pro  
595 600 605

Arg Cys Val Asn Thr Gln Pro Gly Phe His Cys Leu Pro Cys Pro Pro  
610 615 620

Arg Tyr Arg Gly Asn Gln Pro Val Gly Val Gly Leu Glu Ala Ala Lys  
625 630 635 640

Thr Glu Lys Gln Val Cys Glu Pro Glu Asn Pro Cys Lys Asp Lys Thr  
645 650 655

His Asn Cys His Lys His Ala Glu Cys Ile Tyr Leu Gly His Phe Ser  
660 665 670

Asp Pro Met Tyr Lys Cys Glu Cys Gln Thr Gly Tyr Ala Gly Asp Gly  
675 680 685

Leu Ile Cys Gly Glu Asp Ser Asp Leu Asp Gly Trp Pro Asn Leu. Asn  
690 695 700

Leu Val Cys Ala Thr Asn Ala Thr Tyr His Cys Ile Lys Asp Asn Cys  
705 710 715 720

Pro His Leu Pro Asn Ser Gly Gln Glu Asp Phe Asp Lys Asp Gly Ile  
 725 730 735

Gly Asp Ala Cys Asp Asp Asp Asp Asn Asp Gly Val Thr Asp Glu  
740 745 750

Lys Asp Asn Cys Gln Leu Leu Phe Asn Pro Arg Gln Ala Asp Tyr Asp  
755 760 765

Lys Asp Glu Val Gly Asp Arg Cys Asp Asn Cys Pro Tyr Val His Asn  
770 775 780

Pro Ala Gln Ile Asp Thr Asp Asn Asn Gly Glu Gly Asp Ala Cys Ser  
 785            790            795            800

Val Asp Ile Asp Gly Asp Asp Val Phe Asn Glu Arg Asp Asn Cys Pro  
805 810 815

Tyr Val Tyr Asn Thr Asp Gln Arg Asp Thr Asp Gly Asp Gly Val Gly  
820 825 830

Asp His Cys Asp Asn Cys Pro Leu Val His Asn Pro Asp Gln Thr Asp  
835 840 845

Val Asp Asn Asp Leu Val Gly Asp Gln Cys Asp Asn Asn Glu Asp Ile  
850 855 860

Asp Asp Asp Gly His Gln Asn Asn Gln Asp Asn Cys Pro Tyr Ile Ser  
865                    870                    875                    880

Asn Ala Asn Gln Ala Asp His Asp Arg Asp Gly Gln Gly Asp Ala Cys  
..... 885 ..... 890 ..... 895

Asp Pro Asp Asp Asn Asp Gly Val Pro Asp Asp Arg Asp Asn Cys  
900 905 910

Arg Leu Val Phe Asn Pro Asp Gln Glu Asp Leu Asp Gly Asp Gly Arg  
915 920 925

Gly Asp Ile Cys Lys Asp Asp Phe Asp Asn Asp Asn Ile Pro Asp Ile  
930 935 940

Asp Asp Val Cys Pro Glu Asn Asn Ala Ile Ser Glu Thr Asp Phe Arg  
945 950 955 960

Asn Phe Gln Met Val Pro Leu Asp Pro Lys Gly Thr Thr Gln Ile Asp  
965 970 975

Pro Asn Trp Val Ile Arg His Gln Gly Lys Glu Leu Val Gln Thr Ala  
980 985 990

Asn Ser Asp Pro Gly Ile Ala Val Gly Phe Asp Glu Phe Gly Ser Val  
995 1000 1005

Asp Phe Ser Gly Thr Phe Tyr Val Asn Thr Asp Arg Asp Asp Asp  
1010 1015 1020

Tyr Ala Gly Phe Val Phe Gly Tyr Gln Ser Ser Ser Arg Phe Tyr  
1025 1030 1035

Val Val Met Trp Lys Gln Val Thr Gln Thr Tyr Trp Glu Asp Gln  
1040 1045 1050

Pro Thr Arg Ala Tyr Gly Tyr Ser Gly Val Ser Leu Lys Val Val  
1055 1060 1065

Asn Ser Thr Thr Gly Thr Gly Glu His Leu Arg Asn Ala Leu Trp  
1070 1075 1080

His Thr Gly Asn Thr Pro Gly Gln Val Arg Thr Leu Trp His Asp  
1085 1090 1095

Pro Arg Asn Ile Gly Trp Lys Asp Tyr Thr Ala Tyr Arg Trp His  
1100 1105 1110

Leu Thr His Arg Pro Lys Thr Gly Tyr Ile Arg Val Leu Val His  
1115 1120 1125

Glu Gly Lys Gln Val Met Ala Asp Ser Gly Pro Ile Tyr Asp Gln  
1130 1135 1140

Thr Tyr Ala Gly Gly Arg Leu Gly Leu Phe Val Phe Ser Gln Glu  
1145 1150 1155

Met Val Tyr Phe Ser Asp Leu Lys Tyr Glu Cys Arg Asp Ile  
1160 1165 1170